Red Door Wealth Management LLC Purchases 7,300 Shares of Merck & Co., Inc. $MRK

04 Apr 2026, 08:32 by Teresa Graham · The Cerbat Gem

Red Door Wealth Management LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 112,157 shares of the company’s stock after acquiring an additional 7,300 shares during the period. Merck & Co., Inc. accounts for about 1.2% of Red Door Wealth Management LLC’s holdings, making the stock its 22nd biggest position. Red Door Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $11,806,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of MRK. Brighton Jones LLC grew its position in shares of Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after buying an additional 3,941 shares in the last quarter. Edgestream Partners L.P. raised its position in shares of Merck & Co., Inc. by 16.7% in the second quarter. Edgestream Partners L.P. now owns 35,207 shares of the company’s stock worth $2,787,000 after buying an additional 5,049 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Merck & Co., Inc. by 19.3% in the second quarter. EverSource Wealth Advisors LLC now owns 16,796 shares of the company’s stock worth $1,330,000 after buying an additional 2,720 shares in the last quarter. Finally, Kilter Group LLC bought a new stake in Merck & Co., Inc. during the second quarter valued at $27,000. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the topic of a number of research analyst reports. BMO Capital Markets upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Bank of America increased their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, Guggenheim raised their price objective on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $127.13.

Read Our Latest Stock Analysis on Merck & Co., Inc.

Insider Activity at Merck & Co., Inc.

In related news, CEO Robert M. Davis sold 47,434 shares of Merck & Co., Inc. stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the transaction, the chief executive officer owned 443,602 shares in the company, valued at $52,362,780.08. This trade represents a 9.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 320,176 shares of company stock worth $38,281,735 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $120.62 on Friday. The business has a 50 day moving average of $117.72 and a 200 day moving average of $103.08. The company has a market capitalization of $298.21 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to analysts’ expectations of $16.19 billion. During the same period last year, the business earned $1.72 earnings per share. The business’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is 46.70%.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.